<DOC>
	<DOCNO>NCT00001614</DOCNO>
	<brief_summary>Current treatment modality uveitis associate juvenile rheumatoid arthritis beneficial juvenile population . A new approach treat patient presume autoimmune disorder oral tolerance therapy . Chicken type II collagen ( Colloral ) develop oral tolerance therapy treatment rheumatoid arthritis . This open label pilot study describe safety chicken type II collagen add current anti-inflammatory medication treatment patient uveitis associate juvenile rheumatoid arthritis . The primary ophthalmic outcome study change baseline number anterior chamber cell number dosage anti-inflammatory medication . Secondary outcome JRA include change physician 's global assessment , parent/patient assessment overall well-being , functional assessment , number joint active arthritis , number joint limit range motion , erythrocyte sedimentation rate ( ESR ) . Secondary outcome uveitis include change visual acuity , vitreous haze , anterior chamber flare .</brief_summary>
	<brief_title>The Safety Efficacy Chicken Type II Collagen Uveitis Associated With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description>Current treatment modality uveitis associate juvenile rheumatoid arthritis beneficial juvenile population . A new approach treat patient presume autoimmune disorder oral tolerance therapy . Chicken type II collagen ( Colloral ) develop oral tolerance therapy treatment rheumatoid arthritis . This open label pilot study describe safety chicken type II collagen add current anti-inflammatory medication treatment patient uveitis associate juvenile rheumatoid arthritis . The primary ophthalmic outcome study change baseline number anterior chamber cell number dosage anti-inflammatory medication . Secondary outcome JRA include change physician 's global assessment , parent/patient assessment overall well-being , functional assessment , number joint active arthritis , number joint limit range motion , erythrocyte sedimentation rate ( ESR ) . Secondary outcome uveitis include change visual acuity , vitreous haze , anterior chamber flare .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Must meet American College Rheumatology Criteria JRA . Must active anterior uveitis define presence inflammatory cell anterior chamber least one eye , current use topical corticosteroid . Must 2 18 year age , inclusive . Must previous therapy uveitis . Must able undergo slit lamp biomicroscopy assessment anterior chamber cell . Must medium opacity preclude assessment anterior chamber inflammation . Must receive periocular injection corticosteroid within 2 month baseline . Must currently receive DMARD ( disease modify antirheumatic ) therapy , exception prednisone dose great 1.52.0 mg/kg/day , methotrexate dose great 10 mg/m ( 2 ) /week . Must active eye joint inflammation require immediate addition increase systemic antiinflammatory medication . Must involvement prior clinical trial type II collagen . Must exposure within past year shark collagen preparation find health food store . Must history gastrointestinal disease could affect presentation type II collagen . Women must pregnant lactating . Patients currently use Latanoprost , patient use Latanoprost within last 2 week , patient likely need Latanoprost course study exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Eye</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Iritis</keyword>
	<keyword>Joint</keyword>
	<keyword>Oral Tolerance</keyword>
	<keyword>Juvenile Rheumatoid Arthritis</keyword>
	<keyword>Uveitis</keyword>
</DOC>